1. Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P).
- Author
-
Yamauchi, Junji, Tanabe, Kenichiro, Sato, Tomoo, Nakagawa, Masanori, Matsuura, Eiji, Tsuboi, Yoshio, Tamaki, Keiko, Sakima, Hirokuni, Ishihara, Satoshi, Ohta, Yuki, Matsumoto, Naoki, Kono, Kenichi, Yagishita, Naoko, Araya, Natsumi, Takahashi, Katsunori, Kunitomo, Yasuo, Nagasaka, Misako, Coler-Reilly, Ariella, Hasegawa, Yasuhiro, Araujo, Abelardo, Jacobson, Steven, Grassi, Maria, Galvão-Castro, Bernardo, Bland, Martin, Taylor, Graham, Martin, Fabiola, and Yamano, Yoshihisa
- Subjects
HTLV-1-associated myelopathy ,human T-lymphotropic virus type 1 ,methylprednisolone ,prednisolone ,randomized controlled trial ,Adrenal Cortex Hormones ,Aged ,Disabled Persons ,Female ,Human T-lymphotropic virus 1 ,Humans ,Male ,Methylprednisolone ,Middle Aged ,Motor Disorders ,Paraparesis ,Tropical Spastic ,Prednisolone ,Prospective Studies ,Treatment Outcome - Abstract
Corticosteroids are most commonly used to treat HTLV-1-associated myelopathy (HAM); however, their clinical efficacy has not been tested in randomized clinical trials. This randomized controlled trial included 8 and 30 HAM patients with rapidly and slowly progressing walking disabilities, respectively. Rapid progressors were assigned (1:1) to receive or not receive a 3-day course of intravenous methylprednisolone in addition to oral prednisolone therapy. Meanwhile, slow progressors were assigned (1:1) to receive oral prednisolone or placebo. The primary outcomes were a composite of ≥1-grade improvement in the Osame Motor Disability Score or ≥30% improvement in the 10 m walking time (10 mWT) at week 2 for rapid progressors and changes from baseline in 10 mWT at week 24 for slow progressors. In the rapid progressor trial, all four patients with but only one of four without intravenous methylprednisolone achieved the primary outcome (p = 0.14). In the slow progressor trial, the median changes in 10 mWT were -13.8% (95% CI: -20.1--7.1; p < 0.001) and -6.0% (95% CI: -12.8-1.3; p = 0.10) with prednisolone and placebo, respectively (p for between-group difference = 0.12). Whereas statistical significance was not reached for the primary endpoints, the overall data indicated the benefit of corticosteroid therapy. (Registration number: UMIN000023798, UMIN000024085).
- Published
- 2022